Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Acetazolamide for Macular Edema
NCT05290948Phase 2Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acetazolamide in macular edema, sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Best Corrected Visual Acuity at 3 months. Status: unknown.
02
Drugs
acetazolamide
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT05290948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05290948.